Highest-materiality recent filing
GridAI settles $1.03M debt with $800K cash and 71,482 common shares at $3.25/share
Settlement resolves $1,032,315 owed under Revolving Loan Agreement; avoids default demand.
GridAI Technologies Corp. raises ~$7.8M in private placement of common stock and warrants
Gross proceeds of ~$2.54M: 74,000 shares, 1,196,001 pre-funded warrants at $0.00001, and 1,270,001 common warrants at $2.00/unit.
GridAI receives Nasdaq notice for late 10-K filing; 60-day compliance plan deadline
Received Nasdaq deficiency letter on April 22, 2026 for failing to file FY2025 10-K by deadline.
GridAI receives loan default demand for $1.01M from lender
Demand letter received April 1, 2026, asserts default on $700,000 principal under Revolving Loan Agreement.
GridAI Technologies provides acquired GridAI audited financials: $3.3M net loss, going concern
GridAI net loss of $5.3M for inception-to-Sept 2025; $3.3M loss attributable to GridAI on $139K revenue.
GridAI completes rescission of ImmunogenX acquisition, removes $83.2M in assets
Rescission completed Dec 31, 2025; Immuno LLC is no longer a subsidiary.
Jason D. Sawyer appointed permanent CEO effective Dec 19, 2025, transitioning from interim role.
GridAI director Corbett resigns citing governance concerns; ticker changes to GRDX
Director Eric Corbett resigned due to disagreements over financial statement accuracy, GRID AI due diligence, and press release quality.
Entero Therapeutics enters up to $5M securities purchase agreement with initial $500k closing
Initial closing of $500k non-interest bearing promissory note due one year and one day from issuance.
Acquired 100% of GridAI for 424,348 common shares (19.99% of outstanding) and 38,801,546 Series H convertible shares.
Entero Therapeutics replaces Interim CEO; appoints Jason D. Sawyer
Richard Joel Paolone terminated as Interim CEO and Chairman, effective Sept 3, 2025, without cause.
Entero Therapeutics raises $3M in private placement; appoints two new directors
Gross proceeds of $3.0M from sale of pre-funded warrants and common warrants priced at $0.6149 per unit.
Entero Therapeutics shareholders approve reverse stock split authorization at annual meeting
Stockholders authorized a reverse stock split at ratio between 1:2 and 1:20, with board discretion to set ratio within one year.
ImmunogenX subsidiary settled lawsuit with Mattress Liquidators; guarantors paid $5.5M of ~$7.9M owed on Apr 9, 2025.
Entero Therapeutics receives Nasdaq deficiency notice for stockholders' equity shortfall
Stockholders' equity of ($3,876,738) as of Dec 31, 2024, well below Nasdaq's $2.5M minimum.
Entero Therapeutics rescinds 2024 ImmunogenX merger, retains $695K AP; names new CFO
Rescission Agreement with ImmunogenX LLC signed March 24, 2025; unwinds the March 2024 merger.
Nasdaq extends Entero bid price compliance to Sept 1, 2025; CFO resigns, Skowron named CFO
Nasdaq granted extension until Sept 1, 2025 to regain $1.00 minimum bid price compliance.
On March 3, 2025, Ms. Sarah Romano informed the Company of her resignation as Chief Financial Officer of the Company, effective as of March 7, 2025.
on March 3, 2025, the Company appointed Ms. Anna Skowron as Chief Financial Officer of the Company, effective as of March 7, 2025
Max materiality 0.85 · Median 0.65 · Most common event other_material